Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS

PFIZER INC

2024-Q3 EPS reported $1.34 revenue$45,864,000,000

Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.
Reported diluted EPS $0.78 vs. ($0.42) in Q3 2023; adjusted diluted EPS $1.06 vs. ($0.17).
Raised FY 2024 revenue guidance to $61-64B (from $59.5-62.5B) and adjusted EPS to $2.75-2.95 (from $2.45-2.65).
Paxlovid revenue $2.7B (+$2.5B YoY); Comirnaty revenue $1.4B (+9% operational).
Cost reduction program on track for at least $5.5B net savings; $4B expected by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.